376 results on '"Rosmorduc, Olivier"'
Search Results
2. Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT)
3. Immune checkpoints are predominantly co-expressed by clonally expanded CD4+FoxP3+ intratumoral T-cells in primary human cancers
4. Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO – PRODIGE 82)
5. Progressive erythrocytosis under lenvatinib treatment in patients with advanced hepatocellular carcinoma
6. New epidemiologic trends in cholangiocarcinoma
7. THU-491 Prognostic value of the timing of immune checkpoint inhibitors infusion in patients with advanced hepatocellular carcinoma
8. TOP-005 Immune checkpoint inhibitors after liver transplantation: the key role of immunosuppression management
9. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
10. Indocyanine green fluorescence patterns of hepatocellular carcinoma correlate with pathological and molecular features
11. Prognostic value of the timing of immune checkpoint inhibitors infusion in patients with advanced hepatocellular carcinoma.
12. Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors
13. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma
14. Impact on Oncological Outcomes and Intent-to-Treat Survival of Resection Margin for Transplantable Hepatocellular Carcinoma in All-Comers and in Patients with Cirrhosis: A Multicenter Study
15. Hepatocellular Carcinomas With Mutational Activation of Beta-Catenin Require Choline and Can Be Detected by Positron Emission Tomography
16. Immune Checkpoints are Predominantly Co-Expressed by Clonally Expanded CD4+FoxP3+ Intratumoral T-cells in Primary Human Cancers
17. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
18. Liver Resection for Early Hepatocellular Carcinoma: Preoperative Predictors of Non Transplantable Recurrence and Implications for Treatment Allocation
19. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
20. Supplementary Tables and Figures from Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial
21. Supplementary Tables and Figures TC from Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial
22. Supplementary Data from Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma
23. Supplementary Figure S4 from Mitogenic Insulin Receptor-A Is Overexpressed in Human Hepatocellular Carcinoma due to EGFR-Mediated Dysregulation of RNA Splicing Factors
24. Supplementary Figure Legends from Mitogenic Insulin Receptor-A Is Overexpressed in Human Hepatocellular Carcinoma due to EGFR-Mediated Dysregulation of RNA Splicing Factors
25. Data from Mitogenic Insulin Receptor-A Is Overexpressed in Human Hepatocellular Carcinoma due to EGFR-Mediated Dysregulation of RNA Splicing Factors
26. Supplementary Tables S1-S5 from Mitogenic Insulin Receptor-A Is Overexpressed in Human Hepatocellular Carcinoma due to EGFR-Mediated Dysregulation of RNA Splicing Factors
27. Syndrome métabolique, stéatopathie hépatique non alcoolique (NASH) et carcinome hépatocellulaire : des liaisons bien dangereuses...
28. Value of 18-F fluorodeoxyglucose/choline positron emission tomography imaging for predicting hepatocellular carcinoma recurrence after liver transplantation
29. Place of steroids and prognosis factors for grade = 3 immune-checkpoint inhibitors induced hepatitis: a 6-year prospective study
30. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
31. Prevalence of low phospholipid-associated cholelithiasis in young female patients
32. Somatostatin receptors in resected hepatocellular carcinoma: status and correlation with markers of poor prognosis
33. State of the art – hepatocellular carcinoma
34. Advanced epithelioid hemangioendothelioma of the liver: could lenvatinib offer a bridge treatment to liver transplantation?
35. Expression of Defective Hepatitis B (HBV)-DNA, Synthesized from a Singly Spliced HBV-RNA, Leads to Cytoplasmic Accumulation of Capsid and X Proteins
36. Use of choline PET for studying hepatocellular carcinoma
37. Early Versus Late Hepatocellular Carcinoma Recurrence After Transplantation: Predictive Factors, Patterns, and Long-term Outcome
38. Early and resectable HCC: Definition and validation of a subgroup of patients who could avoid liver transplantation
39. The Number of Small Hepatocellular Carcinoma Nodules in Patients within the Alpha-Fetoprotein Score before Liver Transplantation Is a Prognostic Risk Factor
40. Hepatobiliary anomalies associated with ABCB4/MDR3 deficiency in adults: a pictorial essay
41. High trough levels of everolimus combined to sorafenib improve patients survival after hepatocellular carcinoma recurrence in liver transplant recipients
42. Aspects of liver pathology in adult patients with MDR3/ABCB4 gene mutations
43. The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study
44. Tomographie par émission de positons et cancers digestifs
45. Avancées thérapeutiques dans le carcinome hépatocellulaire
46. Number of hepatocellular carcinoma nodules in patients listed for liver transplantation within alpha‐fetoprotein score: a new prognostic risk factor
47. Nivolumab Versus Sorafenib Treatment in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-Label, Phase 3 Trial
48. A new technique for localization of hepatic tumors that are poorly visible with CT fluoroscopy
49. PET/CT in patients with hepatocellular carcinoma using [18F]fluorocholine: preliminary comparison with [18F]FDG PET/CT
50. Atteinte cardiaque de l'hémochromatose
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.